166 related articles for article (PubMed ID: 70492)
1. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
Fisher MW
J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
[TBL] [Abstract][Full Text] [Related]
2. [Natural antibodies against Pseudomonas aeruginosa in human gamma globulin preparations].
Chekan LV; Min'ovich FL; Kutimova LR; Edvabnaia LS; Stanislavskiĭ ES
Zh Mikrobiol Epidemiol Immunobiol; 1981 Jun; (6):85-9. PubMed ID: 6170196
[TBL] [Abstract][Full Text] [Related]
3. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
Collins MS; Roby RE
Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
Cryz SJ; Fürer E; Sadoff JC; Fredeking T; Que JU; Cross AS
J Infect Dis; 1991 May; 163(5):1055-61. PubMed ID: 1902245
[TBL] [Abstract][Full Text] [Related]
5. [The differentiation of OEP-HA titer between gamma-globulin products for intravenous use and their effectiveness in the passive protection of mice against Pseudomonas aeruginosa infection (author's transl)].
Haranaka K; Satomi N; Matsuo M; Fukaya K; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1978 Nov; 52(11):490-6. PubMed ID: 85678
[No Abstract] [Full Text] [Related]
6. Synergistic effect of immune gamma-globulin fraction on protection by antibiotic against corneal ulcers in experimental mice infected with Pseudomonas aeruginosa.
Kawaharajo K; Homma JY
Jpn J Exp Med; 1976 Jun; 46(3):155-65. PubMed ID: 822190
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of the antibody concentration and protective activity against Pseudomonas aeruginosa of gamma-globulin and IgM-enriched immunoglobulin preparations].
Kiseleva IA; Kandiurina VG; Timofeeva GV
Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):68-71. PubMed ID: 2424197
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
9. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
10. [On the problem of gamma globulin therapy of infectious diseases. Passive mice immunity studies with human gamma globulin].
Flury W
Helv Med Acta; 1965 Dec; 32(6):593-602. PubMed ID: 4161844
[No Abstract] [Full Text] [Related]
11. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.
Pollack M
J Infect Dis; 1983 Jun; 147(6):1090-8. PubMed ID: 6406615
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
[TBL] [Abstract][Full Text] [Related]
13. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
Sensakovic JW; Bartell PF
Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of Pseudomonas hyperimmune globulin and plasma.
Jones CE; Alexander JW; Fisher MW
Surg Forum; 1970; 21():238-40. PubMed ID: 4105882
[No Abstract] [Full Text] [Related]
16. Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat.
Dunkley ML; Rajyaguru S; McCue A; Cripps AW; Kyd JM
FEMS Immunol Med Microbiol; 2003 Oct; 39(1):37-44. PubMed ID: 14556994
[TBL] [Abstract][Full Text] [Related]
17. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa.
Davis SD
J Infect Dis; 1975 Jun; 131(6):717-21. PubMed ID: 805814
[TBL] [Abstract][Full Text] [Related]
19. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
Lieberman MM; McKissock DC; Wright GL
Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
Collins MS; Hector RF; Roby RE; Edwards AA; Ladehoff DK; Dorsey JH
Infection; 1987; 15 Suppl 2():S51-9. PubMed ID: 3112021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
